Stark tillväxt Omsättningen i Q2'22 uppgick till 31,9 mkr vilket motsvarar en tillväxt om 144% y/y v...
10% organisk tillväxt Intäkter i Q2'22 uppgick till 192,5 mkr (171,5 mkr i Q2'21), vilket motsvarar ...
Utmanande kvartal… Omsättningen i kvartalet uppgick EUR 6,9m vilket motsvarar en tillväxt om -32% y/...
Utvecklingen har varit stabil i samtliga regioner och fokus ligger på att återfå tidigare momentum o...
High growth in fees and commission Costs falling more than expected from synergies Capital deduction...
Decent NWT ramp-up in Q2, will accelerate in H2 Continued NWC build-up could cause some fears 13-8x ...
Redeye has a positive take on Artificial Solutions’ SaaS metrics, which grew impressively in Q2 2022...
Reassuring Q2 numbers and outlook We raise ‘23e-‘24e estimates Share is trading at 6x ’23e EV/EBITA ...
Q2’22 EBIT of SEK 40m vs. ABGSCe SEK 61m Temporary component shortages hold back sales We lower EBIT...
Raketech just released a somewhat soft Q2 report, and a decent start to Q3.
Netum’s H1 brought no surprises due to given preliminary figures but provided further reassurance of...
Conducting business in Russia becoming more difficult Evaluating a potential divestment 2-7x ’22e-’2...
Redeye comments on today's press release that Safeture has signed a 2-year contract with Innovation ...
Rapporten kommer in enligt förväntan och Plejd fortsätter växa under lönsamhet.
Redeye comments on Amniotics' second quarter report and updates its Base Case.
As expected, Q2 was a softer quarter High activity level expected in H2’22 P/NAV of 0.
Redeye comments on GiG’s Q2-results which came in just above our expectations.
Netum had provided preliminary figures before the H1 results and the earnings report held no surpris...
Redeye increases its forecasts slightly following fx tailwind during Q2’22.
Q2 will likely be negatively affected by market turbulence weighing on Garantia's investment operati...
